Indian stocks: Visit www.stage2stocks.com →

Fate Therapeutics, Inc.

Stage 3 · Topping · week 5

As of Oct 22, 2026, Fate Therapeutics is in Stage 3, the topping phase, now in week 5 (since Sep 23, 2026). It closed at $2.09, 32.8% below its 52-week high and above its 200-day average, which is rising.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. More about the company

$2.09
+0.97% today
$250M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is FATE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 16w
S4 34w
S2 29w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 16w → S1 8w → S2 12w → S3 8w → S4 6w → S1 5w → S4 1w → S1 3w → S4 34w → S1 7w → S4 2w → S1 1w → S4 9w → S1 1w → S2 8w → S3 2w → S4 5w → S1 3w → S2 29w → S3 4w current
Total tracked: 165 weeks across 20 stage runs.

FATE among Biotechnology110th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…110FATEStage 3 · wk 580−14.0%
vs 52W High
-32.8%
$0.96 lo$3.11 hi
32.8% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 5
1w13w26w
Week 5, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
8.5%
200 DMA: $1.93 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.59x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-14.0%
3M
-13.3%
6M
+58.3%
YTD
+111.1%
1Y
+36.6%
Scan Membership
Breakout Watch
Latest: 2024-02-05
6 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 5 · Vol 0.59x
2026-10-21S3
Wk 5 · Vol 0.77x
2026-10-20S3
Wk 4 · Vol 1.21x
2026-10-19S3
Wk 4 · Vol 1.11x
2026-10-16S3
Wk 4 · Vol 0.90x
2026-10-15S3
Wk 4 · Vol 0.74x
2026-10-14S3
Wk 4 · Vol 1.00x
2026-10-13S3
Wk 3 · Vol 0.57x
2026-10-12S3
Wk 3 · Vol 0.36x
2026-10-09S3
Wk 3 · Vol 0.45x
2026-10-08S3
Wk 3 · Vol 0.87x
2026-10-07S3
Wk 3 · Vol 0.50x
Moving averages & range
50 DMA
$2.34
200 DMA
$1.93
52W High
$3.11
52W Low
$0.96
5D Low
$1.79
Resistance levels (recent highs)
20d High
$2.43
60d High
$2.80
120d High
$3.11
250d High
$3.11
Next resistance
+16.3%
to 20d High
ROE
-60.8%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 1.6

Fate Therapeutics: quick answers

What stage is Fate Therapeutics in?

As of Oct 22, 2026, Fate Therapeutics (FATE) is in Stage 3, the topping phase. It entered Stage 3 on Sep 23, 2026 and is in week 5. What the four stages mean

Is Fate Therapeutics in an uptrend?

Its uptrend has stalled. Fate Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 8.5% above its 200-day average, which is rising.

How far is Fate Therapeutics from its 52-week high?

Fate Therapeutics closed at $2.09 on Oct 22, 2026, 32.8% below its 52-week high of $3.11. Its 52-week low is $0.96.

How has Fate Therapeutics performed over the past year?

As of Oct 22, 2026, Fate Therapeutics is up 36.6% over the past year and up 111.1% so far in 2026.

Which sector and industry is Fate Therapeutics in?

Fate Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.